report adjust ep consensu
expect in-lin estim rel forecast better-than-
expect organ growth off-set modest downsid versu estim
adjust oper margin net interest expens minor
zbh revenu increas year-over-year million
consensu expect million estim
million quarter compani organ growth
exceed forecast reflect better-than-anticip perform
product currenc chang reduc revenu growth
year-over-year notabl one extra sale day quarter ad
roughli bp organ growth addit compani suggest
like forward buy japan ahead octob increas
countri consumpt tax appear aid robust asia
pacif organ growth year-over-year
correspond neg impact
want get habit provid quarterli guidanc
result compani chose mere state prior guidanc
includ adjust ep revenu growth year-
over-year unchang notabl compani suggest currenc growth
closer low end prior neg neg
guidanc rang given currenc movement past month
essenti impli compani organ growth toward
higher end prior impli rang regard
continu expect adjust gross margin declin level
given benefit refund prior medic devic excis tax
payment expect reoccur expect neutral impact
foreign currenc hedg contract cog versu benefit
cost increas invest made instrument set throughout
capit start weigh heavili cog said
compani still believ achiev least modest adjust oper margin
total debt total asset
achiev modest upsid consensu expect progress
product categori aid part buy-in activ ahead japan
consumpt tax increas million benefit
correspond neg impact compani result
estim remain larg unchang rais adjust ep
forecast compani reflect lower interest expens
assumpt rate remain neutral
import pleas read disclosur disclaim page report
report adjust ep consensu expect in-lin
estim rel forecast better-than-expect organ growth off-set modest downsid versu
estim adjust oper margin net interest expens minor interest
zbh revenu increas year-over-year million consensu expect
million estim million quarter compani organ growth
exceed forecast reflect better-than-anticip perform product currenc
chang reduc revenu growth year-over-year notabl one extra sale day quarter
ad roughli bp organ growth addit compani suggest like
forward buy japan ahead octob increas countri consumpt tax appear aid
robust asia pacif organ growth year-over-year correspond
neg impact
adjust incom statement analysisnorthcoast research million except percent per share sg interest expens interest expens incom incom incom margin com share compani report northcoast research estim factset
product categori standpoint better-than-anticip perform segment zbh busi
includ hip knee dental product help off-set continu weak
spine/cmf divis notabl call suppli recoveri one factor aid improv result
believ compani also benefit sale forc invest strong market condit
segment addit zbh dental organ growth remain posit territori organ
compani attribut traction invest made late last year referenc one-tim
event drove better-than-anticip perform product busi quarter strong
volum one-tim event offset weaker price neg note zbh spine/cmf
sale remain soft reflect continu weak spine follow late sale forc chang notabl
expect inflect point spine busi earli sale forc chang
anniversari compani better abl support rosa spine launch rosa manufactur capac
primarili use support rosa knee launch
inc organ growth analysi reflect pro forma result zimmer biomet compani report northcoast organ growth analysisnorthcoast currenc constant currenc acquisit divestitur organ hip knee spine cmf dental compani report northcoast research estim knee post organ growth estim quarter knee
implant market growth appear healthi zbh result also benefit initi roll-out rosa
total knee applic contribut less half compani knee organ growth given roughli
million increment knee product sale approxim increment knee product sale rosa
averag sell price rosa knee million rang estim sold roughli rosa total
knee applic unit up-tick zbh knee implant organ growth rel consist across
geographi robust asia pacif result organ improv result emea
organ america organ driven primarili rosa
hip post posit organ growth exceed forecast similar knee
zbh hip busi experienc improv result across geographi led roughli organ growth
emea asia pacif notabl see hip busi one grow around market rate new
product includ avenir complet rosa hip applic road potenti catalyst
inc knee organ growth analysi reflect pro forma result zimmer biometsourc compani report northcoast
zbh adjust oper margin increas bp year-over-year slightli
forecast quarter compani adjust gross margin improv bp year-over-year
quit high anticip given roughli bp benefit refund prior
period medic devic excis tax quarter notabl zbh price growth also modestli weaker
year-over-year versu year-over-year larg reflect one-tim event
achiev strong free cash flow million compani paid million debt
quarter
want get habit provid quarterli guidanc result compani chose mere
state prior guidanc includ adjust ep revenu growth year-
over-year unchang notabl compani suggest currenc growth closer low end
prior neg neg guidanc rang given currenc movement past month
essenti impli compani organ growth toward higher end prior
inc hip organ growth analysi reflect pro forma result zimmer biomet compani report northcoast inc quarterli total compani price growth year-over-year compani impli rang regard continu expect adjust gross margin declin
level given benefit refund prior medic devic excis tax payment
expect reoccur expect neutral impact foreign currenc hedg contract cog versu
benefit cost increas invest made instrument set throughout
capit start weigh heavili cog said compani still believ achiev least
overal achiev modest upsid consensu expect progress product categori
aid part buy-in activ ahead japan consumpt tax increas million benefit
correspond neg impact compani result estim remain
larg unchang rais adjust ep forecast compani reflect
lower interest expens assumpt rate remain neutral
inc annual incom statement analysi adjust northcoast research million except percentag per share gross gross sg sg oper oper net interest incom net interest incom incom incom incom tax minor incom extra incom extra extra net net wghd com share ep ep growth ep growth exclud amort intang asset adjust ep start compani report northcoast research estim disclosur
